Black Diamond Therapeutics (BDTX) Operating Expenses (2018 - 2026)

Black Diamond Therapeutics' Operating Expenses history runs 9 years deep, the most recent figure standing at $11.3 million for Q1 2026.

• Quarterly Operating Expenses fell 27.22% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.3 million (down 28.02% YoY) and the FY2025 annual result came in at $57.5 million, down 27.04% from the prior year.
• Operating Expenses was $11.3 million for Q1 2026 at Black Diamond Therapeutics, down from $17.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $25.7 million in Q1 2022 and bottomed at $11.0 million in Q3 2025.
• A 5-year average of $19.2 million and a median of $20.2 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2024 — Operating Expenses rose 10.47% — and 2025, when it slumped 39.45%.
• Black Diamond Therapeutics' Operating Expenses stood at $21.9 million in 2022, then retreated by 4.56% to $20.9 million in 2023, then declined by 12.37% to $18.3 million in 2024, then retreated by 3.64% to $17.6 million in 2025, then tumbled by 36.06% to $11.3 million in 2026.
• Business Quant data shows BDTX's Operating Expenses at $11.3 million in Q1 2026, $17.6 million in Q4 2025, and $11.0 million in Q3 2025.